A. Scott Pierson

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients

Thomas W. Flaig, Daniel L. Gustafson, Lih‐Jen Su et al. · Investigational New Drugs · 2006 · 317 citations

Medicine, Pharmacokinetics, Pharmacology +11

Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay

Daniel L. Gustafson, Michael E. Long, Joseph A. Zirrolli et al. · Cancer Chemotherapy and Pharmacology · 2003 · 63 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +10

A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors

Samir E. Witta, Daniel L. Gustafson, A. Scott Pierson et al. · Clinical Cancer Research · 2004 · 24 citations

Medicine, Oncology, Pharmacology +14

A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors

Lia Gore, S. Holden, R.B. Cohen et al. · Annals of Oncology · 2006 · 18 citations · Full text

Medicine, Oncology, Pharmacology +11